THE HELLISH REALITY AND TRUTH ABOUT VACCINES HIDDEN IN PLAIN VIEW-SECTION 13 OF THE VACCINE INSERTS


CHECK BELOW FOR THE 83 VACCINES’ MANUFACTURERS’ INSERT INFORMATION (FOR PHYSICIANS) ON SECTION 13WHERE THEY STATE THAT…

NO vaccine has been evaluated for the potential to cause:

  • Cancer
  • Mutate DNA
  • Or Impair Fertility of Both Males and Females

THE SOURCE OF THIS INFORMATION IS THE U.S. FOOD AND DRUG ADMINISTRATION – FDA) –http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm 

In addition, vaccine manufacturers are held to a lower standard than other pharmaceutical, and are not required to do double-blind placebo studies or long-term studies past 6 months, nor have they ever compared vaccinated populations with the unvaccinated! Meanwhile, every person who gets a vaccine is being injured by them.  See VACCINE SUMMARY –http://www.healthalertphilly.org/Vaccines.htm

NOTE: Beware of “patients inserts” are not the same as “physicians inserts” and may not contain the same information.

SAMPLE VACCINE INSERT SECTION:  Section 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility VAXCHORA has not been evaluated for the potential to cause carcinogenicity or genotoxicity, or to impair fertility.e

Trade Name
1.     Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
Section 13, omittted
No Trade Name
2.     Anthrax Vaccine Adsorbed
13. NONCLINICAL TOXICOLOGY The effect of BioThrax on embryo-fetal and pre-weaning development was evaluated in a developmental toxicity study using pregnant rabbits. One group of rabbits was administered BioThrax twice prior to gestation and during the period of organogenesis (gestation day 7). A second group of rabbits was administered BioThrax twice prior to gestation and on gestation day 17. BioThrax was administered at 0.5 ml/rabbit/occasion, by intramuscular injection. No adverse effects on mating, fertility, pregnancy, parturition, lactation, embryo-fetal or preweaning development were observed. There were no vaccine-related fetal malformations or other evidence of teratogenesis noted in this study
Biothrax
3.     BCG Live
BCG VACCINE has not been evaluated for carcinogenic, mutagenic potentials or impairment of fertility.
BCG Vaccine
4.     BCG Live
TICE® BCG has not been evaluated for its carcinogenic, mutagenic potentials or impairment of fertility.
TICE BCG
5.     Cholera Vaccine Live Oral
VAXCHORA has not been evaluated for the potential to cause carcinogenicity or genotoxicity, or to impair fertility.
Vaxchora
6.     Diphtheria & Tetanus Toxoids Adsorbed
Diphtheria and Tetanus Toxoids Adsorbed has not been evaluated for carcinogenicity, mutagenic potential, or impairment of fertility.
No Trade Name
7.     Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
Tripedia vaccine has not been evaluated for its carcinogenic or mutagenic potentials or impairment of fertility.
Tripedia
8.     Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
INFANRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Infanrix
9.     Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
DAPTACEL has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.
DAPTACEL
10.  Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Hepatitis B (recombinant) and Inactivated Poliovirus Vaccine Combined
PEDIARIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Pediarix
11.  Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
KINRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
KINRIX
12.  Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
Quadracel has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.
Quadracel
13.  Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
Pentacel vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.
Pentacel
14.  Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
Liquid PedvaxHIB has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility.
PedvaxHIB
15.  Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
ActHIB vaccine has not been evaluated for its carcinogenic or mutagenic potential or impairment of fertility.
ActHIB
16.  Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)
HIBERIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Hiberix
17.  Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) & Hepatitis B Vaccine (Recombinant)
COMVAX has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.
Comvax
18.  Hepatitis A Vaccine, Inactivated
HAVRIX has not been evaluated for its carcinogenic potential, mutagenic potential, or potential     for impairment of fertility.
Havrix
19.  Hepatitis A Vaccine, Inactivated
VAQTA has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.
VAQTA
20.  Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine
TWINRIX has not been evaluated for its carcinogenic or mutagenic potential, or for impairment of fertility.
Twinrix
21.  Hepatitis B Vaccine (Recombinant)
RECOMBIVAX HB has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility.
Recombivax HB
22.  Hepatitis B Vaccine (Recombinant)
ENGERIX-B has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Engerix-B
23.  Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant
GARDASIL has not been evaluated for the potential to cause carcinogenicity or genotoxicity. GARDASIL administered to female rats at a dose of 120 mcg total protein, which is equivalent to the recommended human dose, had no effects on mating performance, fertility, or embryonic/fetal survival. The effect of GARDASIL on male fertility has been studied in male rats at an intramuscular dose of 0.5 mL/rat/occasion (120 mcg total protein which is equivalent to the recommended human dose). One group of male rats was administered GARDASIL once, 3 days prior to cohabitation, and a second group of male rats was administered GARDASIL three times, at 6 weeks, 3 weeks, and 3 days prior to cohabitation. There were no treatment-related effects on reproductive performance including fertility, sperm count, and sperm motility. There were no treatment-related gross or histomorphologic and weight changes on the testes.
Gardasil
24.  Human Papillomavirus 9-valent Vaccine, Recombinant
GARDASIL 9 has not been evaluated for the potential to cause carcinogenicity, genotoxicity or impairment of male fertility. GARDASIL 9 administered to female rats had no effects on fertility [see Pregnancy (8.1)].
Gardasil 9
25.  Human Papillomavirus Bivalent (Types 16, 18) Vaccine, Recombinant
CERVARIX has not been evaluated for its carcinogenic or mutagenic potential. Vaccination of female rats with CERVARIX, at doses shown to be significantly immunogenic in the rat, had no effect on fertility.
Cervarix
26.  Influenza A (H1N1) 2009 Monovalent Vaccine
Neither Influenza A (H1N1) 2009 Monovalent Vaccine nor AFLURIA has been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.
No Trade Name
27.  Influenza A (H1N1) 2009 Monovalent Vaccine
Neither Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal nor FluMist have been evaluated for carcinogenic or mutagenic potential or potential to impair fertility.
No Trade Name
28.  Influenza A (H1N1) 2009 Monovalent Vaccine
Neither Influenza A (H1N1) 2009 Monovalent Vaccine nor FLULAVAL has been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
No Trade Name
29.  Influenza A (H1N1) 2009 Monovalent Vaccine
Neither FLUVIRIN nor the Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
No Trade Name
30.  Influenza A (H1N1) 2009 Monovalent Vaccine
Neither Fluzone vaccine nor Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
No Trade Name
31.  Influenza Virus Vaccine, H5N1 (for National Stockpile)
Influenza Virus Vaccine, H5N1, has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
No Trade Name
32.  Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted has not been evaluated for carcinogenic or mutagenic potential, or male infertility in animals. Vaccination of female rats with Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted had no effect on fertility [see 385 Pregnancy (8.1)].
No Trade Name
33.  Influenza Vaccine, Adjuvanted
FLUAD has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. FLUAD did not affect female fertility in a rabbit reproductive and developmental toxicity study.
FLUAD
34.  Influenza Vaccine
AFLURIA QUADRIVALENT has not been evaluated for carcinogenic or mutagenic potential, or male infertility in animals. A developmental toxicity study conducted in rats vaccinated with AFLURIA (trivalent formulation) revealed no impact on female fertility (see Pregnancy [8.1]).
AFLURIA QUADRIVALENT
35.  Influenza Vaccine
FLUCELVAX QUADRIVALENT has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. Administration of Flucelvax vaccine (45 mcg HA/dose) did not affect female fertility in a rabbit reproductive and developmental toxicity study.
Flucelvax Quadrivalent
36.  Influenza Virus Vaccine
(Trivalent, Types A and B)

AFLURIA has not been evaluated for carcinogenic or mutagenic potential, or male infertility in animals. A reproductive study of female rats vaccinated with AFLURIA revealed no impairment of fertility (see Pregnancy, 8.1).
Afluria
37.  Influenza Virus Vaccine
(Trivalent, Types A and B)

FLULAVAL has not been evaluated for carcinogenic, mutagenic potential, or male infertility in 15 animals. Vaccination of female rats with FLULAVAL had no effect on fertility [see Use in Specific Populations (8.1)].
FluLaval
38.  Influenza Vaccine, Live, Intranasal
(Trivalent, Types A and B)
FluMist Quadrivalent has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility.
FluMist
39.  Influenza Virus Vaccine
(Trivalent, Types A and B)

FLUARIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Fluarix
40.  Influenza Virus Vaccine
(Trivalent, Types A and B)

FLUVIRIN® has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Fluvirin
41.  Influenza Virus Vaccine
(Trivalent, Types A and B)

AGRIFLU has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility.
Agriflu
42.  Influenza Virus Vaccine
(Trivalent, Types A and B)

Fluzone has not been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.
Fluzone High-Dose has not been evaluated for carcinogenic or mutagenic potential or for impairment of fertility.
Fluzone, Fluzone High-Dose and Fluzone Intradermal
43.  Influenza Virus Vaccine
(Trivalent, Types A and B)

FLUCELVAX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. FLUCELVAX did not affect female fertility in a rabbit reproductive and developmental toxicity study.
Flucelvax
44.  Influenza Vaccine (Trivalent)
Flublok has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. A developmental toxicity study conducted in rats vaccinated with Flublok revealed no evidence of impaired female fertility (see Pregnancy [8.1]).
Flublok
45.  Influenza Vaccine (Quadrivalent)
Flublok Quadrivalent has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. A developmental toxicity study conducted in rats vaccinated with Flublok (trivalent formulation) revealed no evidence of impaired female fertility (see Pregnancy [8.1]).
Flublok Quadrivalent
46.  Influenza Vaccine,Live, Intranasal
(Quadrivalent, Types A and Types B)

FluMist Quadrivalent has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility.
FluMist Quadrivalent
47.  Influenza Virus Vaccine
(Quadrivalent, Types A and Types B)

FLUARIX QUADRIVALENT has not been evaluated for carcinogenic or mutagenic potential or male infertility in animals. Vaccination of female rats with FLUARIX QUADRIVALENT had no effect on fertility [see Use in Specific Populations (8.1)].
Fluarix Quadrivalent
48.  Influenza Virus Vaccine
(Quadrivalent, Types A and Types B)

Fluzone Quadrivalent has not been evaluated for carcinogenic or mutagenic potential. A reproductive study of female rabbits vaccinated with Fluzone Quadrivalent was performed and revealed no evidence of impaired female fertility [see Pregnancy (8.1)].
Fluzone Quadrivalent has not been evaluated for carcinogenic or mutagenic potential. A reproductive study of female rabbits vaccinated with Fluzone Quadrivalent was performed and revealed no evidence of impaired female fertility [see Pregnancy (8.1)].
For: Package Insert – Fluzone Quadrivalent – Southern Hemisphere formulation (PDF – 288KB)Section 13 omitted
Fluzone Quadrivalent
49.  Influenza Virus Vaccine
(Quadrivalent, Types A and Types B)

FLULAVAL QUADRIVALENT has not been evaluated for carcinogenic, mutagenic potential, or male infertility in animals. Vaccination of female rats with FLULAVAL QUADRIVALENT had no effect on fertility [see Use in Specific Populations (8.1)].
FluLaval
Quadrivalent
50.  Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed
IXIARO has not been evaluated for carcinogenic or mutagenic potential. IXIARO was found to have no effect on fertility of female rats at intramuscular doses of up to 300-fold excess relative to the projected human dose (on a mg/kg basis) administered prior to and after mating [See Use in Specific Populations (8.1)]. The effect of IXIARO on male fertility has not been evaluated.
Ixiaro
51.  Japanese Encephalitis Virus Vaccine Inactivated
No studies have been performed to evaluate carcinogenicity, mutagenic potential, or impact on fertility.
JE-Vax
52.   Measles and Mumps Virus Vaccine, Live

M-M-VAX has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility.

M-M-Vax
53.  Measles, Mumps, and Rubella Virus Vaccine, Live
M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility.
M-M-R II
54.  Measles, Mumps, Rubella and Varicella Virus Vaccine Live
ProQuad has not been evaluated for its carcinogenic, mutagenic, or teratogenic potential, or its potential to impair fertility.
ProQuad
55.  Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
MENVEO has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility.
Menveo
56.  Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
MENHIBRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
MenHibrix
57.  Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Menactra has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility. A developmental animal toxicity study showed that Menactra had no effects on female fertility in mice [see Pregnancy (8.1) ].
Menactra
58.  Meningococcal Group B Vaccine
BEXSERO has not been evaluated for carcinogenic or mutagenic potential or impairment of male fertility.
BEXSERO
59.  Meningococcal Group B Vaccine
Trumenba has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility in males.
TRUMENBA
60.  Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined
Menomune – A/C/Y/W-135 vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.
Menomune-A/C/Y/W-135
61.  Plague Vaccine No trade name
62.  Pneumococcal Vaccine, Polyvalent— Section 13 omitted Pneumovax 23
63.  Pneumococcal 7-valent Conjugate Vaccine
(Diphtheria CRM197 Protein)
Prevnar® has not been evaluated for any carcinogenic or mutagenic potential, or impairment of fertility.
Prevnar
64.  Pneumococcal 13-valent Conjugate Vaccine
(Diphtheria CRM197 Protein)
Prevnar 13 has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. In a study in rabbits, no vaccine-related effects were found regarding reproductive performance including female fertility [see Use in Specific Populations (8.1)].
Prevnar 13
65.  Poliovirus Vaccine Inactivated (Human Diploid Cell) – No link Poliovax
66.  Poliovirus Vaccine Inactivated (Monkey Kidney Cell)
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long-term studies in animals to evaluate carcinogenic potential or impairment of fertility have not been conducted.
IPOL
67.  Rabies Vaccine (found no information on carcinogenesis, mutagenesis, or impairment of fertility Imovax
68.  Rabies Vaccine
Long-term studies with RabAvert have not been conducted to assess the potential for carcinogenesis, mutagenesis, or impairment of fertility.
RabAvert
69.  Rabies Vaccine Adsorbed No Trade Name
70.  Rotavirus Vaccine, Live, Oral
ROTARIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
ROTARIX
71.  Rotavirus Vaccine, Live, Oral, Pentavalent
RotaTeq has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility.
RotaTeq
72.  Smallpox (Vaccinia) Vaccine, Live
Section 13 omitted
ACAM2000
73.  Tetanus & Diphtheria Toxoids Adsorbed for Adult Use
No studies have been performed with MassBiologics’ Td to evaluate carcinogenicity, mutagenic potential, or impairment of fertility.
No Trade Name
74.  Tetanus & Diphtheria Toxoids Adsorbed for Adult Use
TENIVAC vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.
TENIVAC
75.  Tetanus Toxoid(Discontinued)
No studies have been performed to evaluate carcinogenicity, mutagenic potential, or impact on fertility.
No Trade Name
76.  Tetanus Toxoid Adsorbed
Diphtheria and Tetanus Toxoids Adsorbed has not been evaluated for carcinogenicity, mutagenic potential, or impairment of fertility.
No Trade Name
77.  Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
Adacel vaccine has not been evaluated for carcinogenic or mutagenic potential, or impairment of fertility.
Adacel
78.  Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
BOOSTRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.
Boostrix
79.  Typhoid Vaccine Live Oral Ty21a
Long-term studies in animals with Vivotif have not been performed to evaluate carcinogenic potential, mutagenic potential or impairment of fertility.
Vivotif
80.  Typhoid Vi Polysaccharide Vaccine
Typhim Vi vaccine has not been evaluated for its carcinogenic potential, mutagenic potential or impairment of fertility.
TYPHIM Vi
81.  Varicella Virus Vaccine Live|
Section 13 is missing!
Pregnancy: Do not administer VARIVAX to females who are pregnant; the possible effects of the vaccine on fetal development are unknown. Pregnancy should be avoided for 3 months following vaccination with VARIVAX. (4.4, 8.1, 17) See 17 for PATIENT COUNSELING INFORMATION and
Varivax
82.  Yellow Fever Vaccine
YF-VAX has not been evaluated for its carcinogenic or mutagenic potential or its effect on fertility.
YF-Vax
83.  Zoster Vaccine, Live, (Oka/Merck)

ZOSTAVAX has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility

Zostavax

Comments are closed.

Copyright © 2013 TheFullertonInformer.com. All rights reserved. TheFullertonInformer.com is the legal copyright holder of the material on this blog and it may not be used, reprinted, or published without express written permission. The information contained in this website is for entertainment and educational purposes ONLY. This website contains my personal opinion and experience based on my own research from scientific writings, internet research and interviews with doctors and scientists all over the world. Do not take this website, links or documents contained herein as a personal, medical or legal advice of any kind. For legal advice, please consult with your attorney. Consult your medical doctor or primary care physician for advice regarding your health and your children’s health and nothing contained on this website is intended to provide or be a substitute for medical, legal or other professional advice. The reading or use of this information is at your own risk. Readers will not be put on spam lists. We will not sell your contact information to another company. We are not responsible for the privacy practices of our advertisers or blog commenters. We reserve the right to change the focus of this blog, to shut it down, to sell it, or to change the terms of use at our discretion. We are not responsible for the actions of our advertisers or sponsors. If a reader purchases a product or service based upon a link from our blog, the reader must take action with that company to resolve the issue, not us. Our policy on using letters or emails that have been written directly to us is as follows: We will be sharing those letters and emails with the blogging audience unless they are requested to be kept confidential. We will claim ownership of those letters or emails to later be used in an up-and-coming book,blog article,post or column, unless otherwise specified by the writer to keep ownership. THE TRUTH WILL STAND ON ITS OWN AND THE TRUTH WILL SET YOU FREE-SEEK IT AT ALL COSTS!